Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Alex on +44 1494 818021 or alex@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alex Reynolds
Account Manager
alex@zenopa.com
+44 1494 818021

Testimonials
I would like to take this opportunity to say thank you for your help and support during the interview process.
Ajay, 2011

Baxter and Sanquin to collaborate on plasma therapy provision

20 July 2012 11:29 in Pharmaceutical Company Product News


Baxter has announced a new collaboration with the Netherlands-based Stichting Sanquin Bloedvoorziening that will help to expand its ability to deliver plasma-derived treatments.

The manufacturing services agreement will provide Baxter with up to 1.6 million litres of incremental plasma fractionation capacity annually, helping the company to meet growing global demand for these therapies.

Sanquin will receive a fixed fee to fractionate plasma used for medications to treat immune disorders, haemophilia, trauma and other critical conditions, with the initial ten-year agreement set to see production commencing in 2014.

This will aid Baxter in the production of treatments such as Kiovig and Flexbumin.

Dr Ludwig Hantson, president of Baxter's bioscience business, said: "Our collaboration with Sanquin is an important step in addressing both the near and long-term needs of the patient community."

This comes after the company announced last month that Kiovig has been approved in the US for the treatment of multifocal motor neuropathy.ADNFCR-8000103-ID-801411745-ADNFCR

Other news stories from 20/07/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd